Management and Board of Directors

Bionovo Management

Isaac Cohen, O.M.D., L.Ac.
Isaac Cohen is a co-founder of Bionovo Pharmaceuticals, Inc. (“Bionovo Pharmaceuticals”), and has served as its Chairman, Chief Executive Officer and Chief Scientific Officer and a Director since February 2002. He became the Company’s Chairman, Chief Executive Officer and Chief Scientific Officer and a Director in April 2005. Mr. Cohen has been a Guest Scientist at the University of California, San Francisco (UCSF) Cancer Research Center and UCSF Center for Reproductive Endocrinology since 1996. Mr. Cohen was in private practice at The American Acupuncture Center, located in Berkeley, California from 1989-2005.

Mary Tagliaferri, M.D., L.Ac.
Dr. Tagliaferri has over 15 years experience in translational research with the University of California, San Francisco and Bionovo, Inc. Dr. Tagliaferri has spearheaded multiple scientific R&D projects to develop pharmaceutical agents for indications in women's health and cancer. As one of the co-founders of Bionovo, Inc., she has extensive experience with FDA regulatory affairs and she has successfully filed a number of Investigational New Drug Licenses (INDs). She has been involved in all aspects of drug development, from preclinical testing to developing FDA approved protocols for clinical trials. As the President, Chief Medical Officer and Chief Regulatory Officer of Bionovo, she manages and directs the daily activities of all clinical research projects that have been outsourced to prestigious medical centers throughout the United States and abroad. Dr. Tagliaferri, a graduate from Cornell University, received her medical degree from the University of California, San Francisco. She also holds a Master's degree in traditional Chinese medicine from the American College of Traditional Chinese Medicine.

Thomas C. Chesterman
Thomas Chesterman has served as our Senior Vice President and Chief Financial Officer since July 2007. From June 2002 to January 2007, Mr. Chesterman was Senior Vice President and Chief Financial Officer at Aradigm Corporation. From March 1996 to December 2001, Mr. Chesterman was Vice President and Chief Financial Officer at Bio-Rad Laboratories, Inc., a life-science research products and clinical diagnostics company. From 1993 to 1996, Mr. Chesterman was Vice President of Strategy and Chief Financial Officer of Europolitan AB, a telecommunications company. Mr. Chesterman holds a B.A. from Harvard University and an M.B.A. in Finance and Accounting from the University of California at Davis.

Bionovo Board of Directors

Isaac Cohen, O.M.D., L.Ac.
Isaac Cohen is a co-founder of Bionovo Pharmaceuticals, Inc. (“Bionovo Pharmaceuticals”), and has served as its Chairman, Chief Executive Officer and Chief Scientific Officer and a Director since February 2002. He became the Company’s Chairman, Chief Executive Officer and Chief Scientific Officer and a Director in April 2005. Mr. Cohen has been a Guest Scientist at the University of California, San Francisco (UCSF) Cancer Research Center and UCSF Center for Reproductive Endocrinology since 1996. Mr. Cohen was in private practice at The American Acupuncture Center, located in Berkeley, California from 1989-2005.

Mary Tagliaferri, M.D., L.Ac.
Dr. Tagliaferri has over 15 years experience in translational research with the University of California, San Francisco and Bionovo, Inc. Dr. Tagliaferri has spearheaded multiple scientific R&D projects to develop pharmaceutical agents for indications in women's health and cancer. As one of the co-founders of Bionovo, Inc., she has extensive experience with FDA regulatory affairs and she has successfully filed a number of Investigational New Drug Licenses (INDs). She has been involved in all aspects of drug development, from preclinical testing to developing FDA approved protocols for clinical trials. As the President, Chief Medical Officer and Chief Regulatory Officer of Bionovo, she manages and directs the daily activities of all clinical research projects that have been outsourced to prestigious medical centers throughout the United States and abroad. Dr. Tagliaferri, a graduate from Cornell University, received her medical degree from the University of California, San Francisco. She also holds a Master's degree in traditional Chinese medicine from the American College of Traditional Chinese Medicine.

David Naveh, Ph.D., MBA
Dr. Naveh retired from Bayer Corporation in 2007, where he had worked since 1992, and served as Chief Technological Officer of Bayer Biological Products, Worldwide.  Prior to Bayer, Dr. Naveh was responsible for antibody production at Centocor and led the CMC commercialization of Centoxin, Remocaid and Reopro.  Before that, David was a manager at Schering Plough and participated in Intron and Gentamacyin development.  Dr. Naveh is a member of the Company’s Audit, and the Compensation, and Nominations committees.

Michael Vanderhoof
Mr. Vanderhoof is Chairman of Cambria Asset Management, LLC, which owns Cambria Capital, LLC, a NASD registered broker dealer with offices in Los Angeles, Salt Lake City. Mr. Vanderhoof is also a co-manager of Cambria Investment Fund LP. Mr. Vanderhoof has over 23 years of experience in the capital markets. Mr. Vanderhoof is also a director of Auxilio, Inc.

Louis Drapeau
Mr. Drapeau is currently the CEO and CFO of Insite Vision Incorporated. From January 2006 to August 2007 he served as Chief Financial Officer, Senior Vice President, Finance at Nektar Therapeutics where he managed accounting, financial planning, information technology, internal auditing and investor relations for the biopharmaceutical company headquartered in San Carlos, California. Prior to Nektar, he served as Acting Chief Executive Officer from August 2004 to May 2005 and as Senior Vice President and Chief Financial Officer from August 2002 to August 2005 for BioMarin Pharmaceutical Inc. Previously, Drapeau spent 30 years at Arthur Andersen including 19 years as an Audit Partner in Arthur Andersen’s Northern California Audit and Business Consulting practice which included 12 years as Managing Partner.  He serves as AC Chair, Director and Member of the Audit Committee of Bio-Rad Laboratories as well as AC Chair, Director and Member of the Audit and Compensation Committees of InterMune, Inc.

John D. Baxter, M.D.
Dr. Baxter is currently Senior Member and Co-Director of the Center for Diabetes Research at The Methodist Hospital Research Institute and Head of Endocrinology at the Methodist Hospital. He was associated with the University of California, San Francisco (“UCSF”) from 1970 to 2008 where he was a Professor of Medicine from 1979 to 2008, Chief of the Endocrinology, Parnassus Campus from 1980 to 1997, and Director of UCSF’s Metabolic Research Unit from 1981 to 1999. Dr. Baxter was President of The Endocrine Society from June 2002 to June 2003. He was a Founder and served as a Director of California Biotechnology, Inc., a drug development company (now Scios, Inc., a division of Johnson & Johnson) from 1982 until 1992, and was a founder and Director of Karo Bio A.B., a Swedish biotechnology company and SciClone Pharmaceuticals, a drug development company. Dr. Baxter was elected to the National Academy of Sciences and the Institute of Medicine of the National Academy of Sciences, and he received the Outstanding Investigator Award from the Howard Hughes Medical Institute. Dr. Baxter serves on our Audit Committee, and on our Compensation and Nominations Committee.

George C. Butler, Ph.D.
Dr. Butler is currently President of SingEval Inc. He has over 32 years of development experience on a global basis in ‘big pharma’. Dr. Butler has also been active for many years in advancing Asian-Western development/regulatory single programs. His industry experience includes R&D leadership team membership at pharmaceutical vanguards AstraZeneca and Novartis, where he also headed the global Regulatory Affairs teams. Dr. Butler holds his doctorate from the University of Manchester, UK. He has chaired and spoken at many global healthcare industry and regulatory authority meetings. Dr. Butler has also been a long time valued member of the Regulatory Advisory Board of the Centre for Medicines Research; he has chaired the European Licensing section of the UK government/industry sponsored competitiveness initiative (PICTF); and has participated in the UK government’s Supervisory Board for the MCA. He has been on the boards of several non-profits and for-profit companies, and is a senior advisor to the non-profit US IVB (Initiative for Value-Based Preventive Medicine).